Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Aquino, Domenico ^a   Di Stefano, Anna Luisa ^b   Scotti, Alessandro ^a   Cuppini, Lucia ^a   Anghileri, Elena ^a   Finocchiaro, Gaetano ^a   Bruzzone, Maria Grazia ^a   Eoli, Marica ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN BLOOD VOLUME; BRAIN PERFUSION; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; MALE; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; WHITE MATTER; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; SCINTIGRAPHY; SURVIVAL; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERFUSION IMAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899842077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090535     Document Type: Article

References (33)

1. McNamara MG, Mason WP (2012) Antiangiogenic therapies in glioblastoma multiforme. Expert Rev Anticancer Ther 12: 643-654.
2. Specenier P (2012) Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther 12: 9-18.
3. Lu KV, Bergers G (2013) Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2: 49-65.
4. Maru D, Venook AP, Ellis LM (2013) Predictive biomarkers for bevacizumab: Are we there yet? Clin Cancer Res 19: 2824-2827.
5. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, et al. (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402-407.
6. Cha S, Knopp EA, Johnson G, Litt A, Glass J, et al. (2000) Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 21: 881-890. (Pubitemid 30262835)
7. Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, et al. (2010) Glioblastoma: A method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology 255: 622-628.
8. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, et al. (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15: 572-576.
9. Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, et al. (2010) Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 28: 2293-2299.
10. Law M, Young R, Babb J, Pollack E, Johnson G (2007) Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. AJNR Am J Neuroradiol 28: 761-766. (Pubitemid 46608621)
11. Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, et al. (2013) Prognostic value of CD109 + circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One In press.
12. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
13. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
14. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, et al. (2011) Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 32: 882-889.
15. Chamberlain MC (2011) Radiographic patterns of relapse in glioblastoma. J Neurooncol 101: 319-323.
16. Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, et al. (2008) Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247: 490-498.
17. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, et al. (2005) Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102: 5524-5529. (Pubitemid 40530291)
18. Van Meter ME, Kim ES (2010) Bevacizumab: Current updates in treatment. Curr Opin Oncol 22: 586-591.
19. Barajas RF,Jr, Cha S (2012) Imaging diagnosis of brain metastasis. Prog Neurol Surg 25: 55-73.
20. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7: 987-989.
21. Maier SE, Sun Y, Mulkern RV (2010) Diffusion imaging of brain tumors. NMR Biomed 23: 849-864.
22. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, et al. (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multicenter study. J Neurooncol 108: 491-498.
23. Zulfiqar M, Yousem DM, Lai H (2013) ADC values and prognosis of malignant astrocytomas: Does lower ADC predict a worse prognosis independent of grade of tumor?-a meta-analysis. AJR Am J Roentgenol 200: 624-629.
24. Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, et al. (2004) Expression of CD109 in human cancer. Oncogene 23: 3716-3720. (Pubitemid 38658439)
25. Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, et al. (2013) Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro Oncol 15: 936-944.
26. Takano S, Kimu H, Tsuda K, Osuka S, Nakai K, et al. (2013) Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab. Acta Neurochir Suppl 118: 185-189.
27. Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, et al. (2012) Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent highgrade glioma. AJNR Am J Neuroradiol 33: 69-76.
28. Mills SJ, Soh C, O'Connor JP, Rose CJ, Buonaccorsi G, et al. (2010) Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: A dynamic contrast-enhancedMRimaging study. AJNR AmJ Neuroradiol 31: 726-731.
29. Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, et al. (2000) Posttherapeutic intraaxial brain tumor: The value of perfusion-sensitive contrastenhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 21: 901-909. (Pubitemid 30262837)
30. Young R, Babb J, Law M, Pollack E, Johnson G (2007) Comparison of region-of- interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 26: 1053-1063. (Pubitemid 47548167)
31. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, et al.(2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. PNAS,2013 Nov;110(47):19059-64.
32. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, et al. (2011) Prospective analysis of parametric response map-derived MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 17: 4751-4760.
33. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.